Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients
Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients.
- Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients
Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients.
- Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients
Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients.
- Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients
Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients.
- Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients
Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients.
- Industry Coalition Advises Against Use of Dietary Supplements as Remedy for Avian Flu
The trade associations of the dietary supplement industry urge industry to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu, refrain from promoting any dietary supplement as a preventative, cure or treatment for avian flu, and arge those who believe they may have avian flu or may have come in contact with it should immediately contact a healthcare professional.
- Industry Coalition Advises Against Use of Dietary Supplements as Remedy for Avian Flu
The trade associations of the dietary supplement industry urge industry to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu, refrain from promoting any dietary supplement as a preventative, cure or treatment for avian flu, and arge those who believe they may have avian flu or may have come in contact with it should immediately contact a healthcare professional.
- Industry Coalition Advises Against Use of Dietary Supplements as Remedy for Avian Flu
The trade associations of the dietary supplement industry urge industry to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu, refrain from promoting any dietary supplement as a preventative, cure or treatment for avian flu, and arge those who believe they may have avian flu or may have come in contact with it should immediately contact a healthcare professional.
- Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims
Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake.
- Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims
Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake.
- Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims
Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake.
- New Scholarship to Honor the Late Dr. Khem Shahani
A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria.
- New Scholarship to Honor the Late Dr. Khem Shahani
A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria.
- New Scholarship to Honor the Late Dr. Khem Shahani
A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria.
- Solbar Restructures for New Challenges
Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division.
- Solbar Restructures for New Challenges
Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division.
- Solbar Restructures for New Challenges
Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division.
- Solbar Restructures for New Challenges
Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division.
- Solbar Restructures for New Challenges
Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division.
- FSANZ Invites Comment About Draft Health Claims Standard
Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition.
- FSANZ Invites Comment About Draft Health Claims Standard
Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition.
- FSANZ Invites Comment About Draft Health Claims Standard
Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition.
- FSANZ Invites Comment About Draft Health Claims Standard
Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition.
- FSANZ Invites Comment About Draft Health Claims Standard
Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition.
- Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein
Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure.
- Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein
Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure.
- Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein
Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure.
- Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein
Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure.
- Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein
Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure.
- Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression
randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant.
- Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression
randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant.
- Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression
randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant.
- Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression
randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant.
- Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression
randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant.
- AEterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S.
Atrium Biotechnologies Inc. has acquired HVL Inc., whose main brand is Douglas Laboratories for the total amount of $107 million ($US 92 million), approximately 6.4 times the adjusted EBITDA generated by Douglas.
- AEterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S.
Atrium Biotechnologies Inc. has acquired HVL Inc., whose main brand is Douglas Laboratories for the total amount of $107 million ($US 92 million), approximately 6.4 times the adjusted EBITDA generated by Douglas.
- AEterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S.
Atrium Biotechnologies Inc. has acquired HVL Inc., whose main brand is Douglas Laboratories for the total amount of $107 million ($US 92 million), approximately 6.4 times the adjusted EBITDA generated by Douglas.
- Health Wright Products Announces Major Expansion
Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006.
- Health Wright Products Announces Major Expansion
Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006.
- Health Wright Products Announces Major Expansion
Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006.
- Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study
An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier.
- Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study
An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier.
- Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study
An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier.
- 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada
Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada.
- 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada
Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada.
- 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada
Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada.
- 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada
Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada.
- 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada
Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada.
- Celanese Has Sold Its omega-3 DHA Business to Lonza
Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed.
- Celanese Has Sold Its omega-3 DHA Business to Lonza
Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed.
- Celanese Has Sold Its omega-3 DHA Business to Lonza
Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed.
- Celanese Has Sold Its omega-3 DHA Business to Lonza
Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed.
- ORAFTI’s Synergy 1® Receives Natural Products Award
Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards.
- ORAFTI’s Synergy 1® Receives Natural Products Award
Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards.
- ORAFTI’s Synergy 1® Receives Natural Products Award
Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements
EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising.
- Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana
Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC).
- Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana
Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC).
- Calcium May Only Protect Against Colorectal Cancer in Presence of Magnesium
According to data presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research, an understanding of the relationship between calcium and magnesium may lead to new avenues of personalized prevention for colorectal cancer.
- Calcium May Only Protect Against Colorectal Cancer in Presence of Magnesium
According to data presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research, an understanding of the relationship between calcium and magnesium may lead to new avenues of personalized prevention for colorectal cancer.
- Calcium May Only Protect Against Colorectal Cancer in Presence of Magnesium
According to data presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research, an understanding of the relationship between calcium and magnesium may lead to new avenues of personalized prevention for colorectal cancer.
- ON's Pro Complex® Augmented Protein System Goes Natural
- ON's Pro Complex® Augmented Protein System Goes Natural
- ON's Pro Complex® Augmented Protein System Goes Natural
- ON's Pro Complex® Augmented Protein System Goes Natural
- ON's Pro Complex® Augmented Protein System Goes Natural
- Trace Minerals Research Releases New and Improved Performance Electrolyte Formula
Trace Minerals Research is now offering a new and improved formula of Electrolyte Stamina Tablets, an electrolyte replacement supplement designed for individuals that expend large amounts of electrolytes during strenuous activities. Electrolyte Stamina Tablets now contain P-5-P and L-Taurine.
- Trace Minerals Research Releases New and Improved Performance Electrolyte Formula
Trace Minerals Research is now offering a new and improved formula of Electrolyte Stamina Tablets, an electrolyte replacement supplement designed for individuals that expend large amounts of electrolytes during strenuous activities. Electrolyte Stamina Tablets now contain P-5-P and L-Taurine.
- Trace Minerals Research Releases New and Improved Performance Electrolyte Formula
Trace Minerals Research is now offering a new and improved formula of Electrolyte Stamina Tablets, an electrolyte replacement supplement designed for individuals that expend large amounts of electrolytes during strenuous activities. Electrolyte Stamina Tablets now contain P-5-P and L-Taurine.
- Natural Nutrition Reports Comprehensive Income of $2,062,452 Through FY08 Q3
Natural Nutrition, Inc., has reported net income of $2,062,452 (unaudited) for the first nine months of 2008 through September 30th versus losses of $3,744,404 through the same first nine months of 2007. These numbers are unaudited and subject to revision.
- Natural Nutrition Reports Comprehensive Income of $2,062,452 Through FY08 Q3
Natural Nutrition, Inc., has reported net income of $2,062,452 (unaudited) for the first nine months of 2008 through September 30th versus losses of $3,744,404 through the same first nine months of 2007. These numbers are unaudited and subject to revision.
- Natural Nutrition Reports Comprehensive Income of $2,062,452 Through FY08 Q3
Natural Nutrition, Inc., has reported net income of $2,062,452 (unaudited) for the first nine months of 2008 through September 30th versus losses of $3,744,404 through the same first nine months of 2007. These numbers are unaudited and subject to revision.
- Nutraceutical Reports FY08 End Results
Nutraceutical International Corporation has announced the results for the fiscal 2008 fourth quarter and year ended September 30, 2008. Net sales for the fiscal year ended September 30, 2008 were $166.9 million compared to $156.5 million for fiscal 2007. For fiscal 2008, net income was $11.9 million (including the $1.8 million goodwill impairment charge), or $1.07 diluted earnings per share (including the goodwill impairment charge of $0.16 per share), compared to net income of $13.0 million (including the $0.3 million intangible asset impairment charge), or $1.15 diluted earnings per share (including the intangible asset impairment charge of $0.02 per share), for fiscal 2007.
- Nutraceutical Reports FY08 End Results
Nutraceutical International Corporation has announced the results for the fiscal 2008 fourth quarter and year ended September 30, 2008. Net sales for the fiscal year ended September 30, 2008 were $166.9 million compared to $156.5 million for fiscal 2007. For fiscal 2008, net income was $11.9 million (including the $1.8 million goodwill impairment charge), or $1.07 diluted earnings per share (including the goodwill impairment charge of $0.16 per share), compared to net income of $13.0 million (including the $0.3 million intangible asset impairment charge), or $1.15 diluted earnings per share (including the intangible asset impairment charge of $0.02 per share), for fiscal 2007.
- Nutraceutical Reports FY08 End Results
Nutraceutical International Corporation has announced the results for the fiscal 2008 fourth quarter and year ended September 30, 2008. Net sales for the fiscal year ended September 30, 2008 were $166.9 million compared to $156.5 million for fiscal 2007. For fiscal 2008, net income was $11.9 million (including the $1.8 million goodwill impairment charge), or $1.07 diluted earnings per share (including the goodwill impairment charge of $0.16 per share), compared to net income of $13.0 million (including the $0.3 million intangible asset impairment charge), or $1.15 diluted earnings per share (including the intangible asset impairment charge of $0.02 per share), for fiscal 2007.
- Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition
Health ingredients Europe and Natural ingredients 2008, the global events for the health and natural ingredients industries, recorded more than a 7%* increase in attendance at the biennial event, which took place on 4-6 November 2008 in Paris, France.
- Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition
Health ingredients Europe and Natural ingredients 2008, the global events for the health and natural ingredients industries, recorded more than a 7%* increase in attendance at the biennial event, which took place on 4-6 November 2008 in Paris, France.
- Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition
Health ingredients Europe and Natural ingredients 2008, the global events for the health and natural ingredients industries, recorded more than a 7%* increase in attendance at the biennial event, which took place on 4-6 November 2008 in Paris, France.
- Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition
Health ingredients Europe and Natural ingredients 2008, the global events for the health and natural ingredients industries, recorded more than a 7%* increase in attendance at the biennial event, which took place on 4-6 November 2008 in Paris, France.
- Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition
Health ingredients Europe and Natural ingredients 2008, the global events for the health and natural ingredients industries, recorded more than a 7%* increase in attendance at the biennial event, which took place on 4-6 November 2008 in Paris, France.
- Lifeway Foods Announces New West Coast Distribution
Lifeway Foods, Inc., has announced new distribution of its ProBugs(TM) Organic Kefir in the northern California region through Costco. ProBugs(TM) Organic Kefir, which is geared towards children, comes in a patented no-spill pouch and will be sold in a twelve unit multi-pack consisting of kid friendly flavors, Orange Creamy Crawler(TM) and Goo Berry Pie(TM). Shipments will begin in the third week of December 2008.
- Lifeway Foods Announces New West Coast Distribution
Lifeway Foods, Inc., has announced new distribution of its ProBugs(TM) Organic Kefir in the northern California region through Costco. ProBugs(TM) Organic Kefir, which is geared towards children, comes in a patented no-spill pouch and will be sold in a twelve unit multi-pack consisting of kid friendly flavors, Orange Creamy Crawler(TM) and Goo Berry Pie(TM). Shipments will begin in the third week of December 2008.
- Lifeway Foods Announces New West Coast Distribution
Lifeway Foods, Inc., has announced new distribution of its ProBugs(TM) Organic Kefir in the northern California region through Costco. ProBugs(TM) Organic Kefir, which is geared towards children, comes in a patented no-spill pouch and will be sold in a twelve unit multi-pack consisting of kid friendly flavors, Orange Creamy Crawler(TM) and Goo Berry Pie(TM). Shipments will begin in the third week of December 2008.
- Lifeway Foods Announces New West Coast Distribution
Lifeway Foods, Inc., has announced new distribution of its ProBugs(TM) Organic Kefir in the northern California region through Costco. ProBugs(TM) Organic Kefir, which is geared towards children, comes in a patented no-spill pouch and will be sold in a twelve unit multi-pack consisting of kid friendly flavors, Orange Creamy Crawler(TM) and Goo Berry Pie(TM). Shipments will begin in the third week of December 2008.
- Lifeway Foods Announces New West Coast Distribution
Lifeway Foods, Inc., has announced new distribution of its ProBugs(TM) Organic Kefir in the northern California region through Costco. ProBugs(TM) Organic Kefir, which is geared towards children, comes in a patented no-spill pouch and will be sold in a twelve unit multi-pack consisting of kid friendly flavors, Orange Creamy Crawler(TM) and Goo Berry Pie(TM). Shipments will begin in the third week of December 2008.
- Symrise Obtains Exclusive Marketing Rights to New Cosmetic Active Ingredients
Symrise has acquired licenses for two new groups of cosmetic active ingredients. These promising results were achieved in a joint development project with biotech specialist BRAIN and natural-product company AnalytiCon. The license gives Symrise international marketing rights.
- Symrise Obtains Exclusive Marketing Rights to New Cosmetic Active Ingredients
Symrise has acquired licenses for two new groups of cosmetic active ingredients. These promising results were achieved in a joint development project with biotech specialist BRAIN and natural-product company AnalytiCon. The license gives Symrise international marketing rights.
- Symrise Obtains Exclusive Marketing Rights to New Cosmetic Active Ingredients
Symrise has acquired licenses for two new groups of cosmetic active ingredients. These promising results were achieved in a joint development project with biotech specialist BRAIN and natural-product company AnalytiCon. The license gives Symrise international marketing rights.
- Mannatech Declares Dividend
Mannatech, Incorporated has announced that its Board of Directors declared a quarterly cash dividend on Wednesday, November 19, 2008 of $0.02 per share of common stock payable on Monday, December 29, 2008, to shareholders of record at the close of business on Thursday, December 11, 2008.
- Mannatech Declares Dividend
Mannatech, Incorporated has announced that its Board of Directors declared a quarterly cash dividend on Wednesday, November 19, 2008 of $0.02 per share of common stock payable on Monday, December 29, 2008, to shareholders of record at the close of business on Thursday, December 11, 2008.
- Mannatech Declares Dividend
Mannatech, Incorporated has announced that its Board of Directors declared a quarterly cash dividend on Wednesday, November 19, 2008 of $0.02 per share of common stock payable on Monday, December 29, 2008, to shareholders of record at the close of business on Thursday, December 11, 2008.
- NPI Daily - Top of The News for November 20, 2008 - Marketers of Dietary Supplements Ordered to Halt False Claims About Diabetes Prevention and Treatment
Symrise Obtains Exclusive Marketing Rights to New Cosmetic Active Ingredients; Natural Nutrition Reports Comprehensive Income of $2,062,452 Through FY08 Q3; Nutraceutical Reports FY08 End Results; Mannatech Declares Dividend; Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition; Calcium May Only Protect Against Colorectal Cancer in Presence of Magnesium; Marketers of Dietary Supplements Ordered to Halt False Claims About Diabetes Prevention and Treatment; PC Brands Introduces Shelf-Stable Nutrition Bar With Probiotics; Lifeway Foods Announces New West Coast Distribution; Trace Minerals Research Releases New and Improved Performance Electrolyte Formula
- NPI Daily - Top of The News for November 20, 2008 - Marketers of Dietary Supplements Ordered to Halt False Claims About Diabetes Prevention and Treatment
Symrise Obtains Exclusive Marketing Rights to New Cosmetic Active Ingredients; Natural Nutrition Reports Comprehensive Income of $2,062,452 Through FY08 Q3; Nutraceutical Reports FY08 End Results; Mannatech Declares Dividend; Hi Europe & Ni 2008 Attendance Grows 7% on Previous Edition; Calcium May Only Protect Against Colorectal Cancer in Presence of Magnesium; Marketers of Dietary Supplements Ordered to Halt False Claims About Diabetes Prevention and Treatment; PC Brands Introduces Shelf-Stable Nutrition Bar With Probiotics; Lifeway Foods Announces New West Coast Distribution; Trace Minerals Research Releases New and Improved Performance Electrolyte Formula
|
Searchable AHPA NDI Database Developed by AHPA and NPIcenter
The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database to access all notifications the Food and Drug Administration (FDA) has received for new dietary ingredients (NDIs). The AHPA NDI Database launches on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period begins.
The database can be searched by numerous relevant fields, including the generic or brand name of every 75-day notice (botanical and non-botanical), the Latin binomial of herbs, and the name of the company that made the submission. The database also provides a concise “outcome statement” for each file that quickly summarize how FDA has responded to every notification, and the problems, if any, that the agency identified for each.
“New ingredients are key to the supplement industry’s future and the AHPA NDI Database will be a valuable resource for firms that are filing the required notification prior to marketing an NDI, said Michael McGuffin, president of AHPA. “By accessing and reviewing other relevant NDI notifications, companies will be better prepared to file complete submissions and thereby prevent delays to market entry.”
The Dietary Supplement Health and Education Act (DSHEA) requires manufacturers or distributors of an NDI — an ingredient not sold before DSHEA went into effect in 1994 — to provide information to FDA that is the basis for a conclusion that the ingredient is reasonably expected to be safe (New dietary ingredients that are articles used as food in a form in which the food has not been chemically altered are exempt form the notification requirement described here.).
Since DSHEA passed, FDA has posted almost 300 NDI notifications on its dockets website. However, the only organization provided is by the FDA-assigned report numbers, which makes individual reports very difficult to locate. Even when found, it is impossible to know without opening and examining the entire file (which can run to hundreds of pages) whether a filing was successful or whether (and why) FDA objected to the notification. The AHPA NDI Database was specifically designed to provide faster and more informative access to filed notifications.
The database will be maintained on an ongoing basis; future NDI filings and FDA responses will be promptly added to the system. Special introductory access fees for AHPA members are $125 per year per site / $40 per day per site, and for non-members are $495 per year per site / $125 per day per site. The open-access trial period runs 9 a.m.–6 p.m. Eastern, Monday, December 5, only.
The AHPA NDI Database is accessible at http://ndi.npicenter.com/. |